drugset / Trial / NCT06900088
Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients
NaSingle-groupOpen-labelTreatment
Summary
Efficacy and Safety of Selinexor Combined with Azacitidine as Maintenance Therapy in High-Risk Myeloid Neoplasms Patients Post-Transplantation: A Single-Center, Single-Arm, Exploratory Study
Timeline
- Start
- 2025-04-25
- Primary completion
- 2025-10-30
- Completion
- 2026-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selinexor | Other / unclassified | 40 mg | — |
| Background | Azacitidine | Other / unclassified | 50 mg/m2 | — |